Mymetics Corporation
Mymetics is a pioneer in the research and development of virosome-based vaccines aimed at preventing transmission of human infectious diseases. The company has been involved in developing vaccines for HIV, malaria, influenza, and other infectious diseases, utilizing innovative vaccine platforms such as virosomes and mucosal immunization strategies. Despite recent restructuring and winding down of operations as of March 2024, Mymetics has contributed significantly to vaccine research, including groundbreaking studies and collaborations with global health initiatives.
Industries
Nr. of Employees
small (1-50)
Mymetics Corporation
Patents
Products
HIV-1 mucosal vaccine candidate (gp41-based)
A virosome-formulated HIV-1 vaccine candidate incorporating gp41 subunit antigens intended to induce mucosal antibodies and prevent mucosal transmission; evaluated in preclinical models and a Phase I trial.
Malaria transmission-blocking virosome vaccine candidate
Virosome-based formulations containing malaria antigens developed to reduce or block transmission of Plasmodium falciparum in preclinical models.
Respiratory syncytial virus (RSV) virosomal vaccine with MPLA adjuvant
Virosome-formulated RSV vaccine candidates incorporating a membrane-incorporated monophosphoryl lipid A adjuvant evaluated for immunogenicity and protective capacity in preclinical models.
Allergy immunotherapy using peptide antigens linked to virosomes
Preclinical formulations combining contiguous overlapping peptides (COPs) with virosome carriers aimed at allergen immunotherapy with potential for shortened administration schemes.
Partner cancer immunotherapy vaccine manufacturing
Manufacture and development services for a partner cancer immunotherapy vaccine candidate under an exclusive agreement to support upcoming clinical evaluation.
HIV-1 mucosal vaccine candidate (gp41-based)
A virosome-formulated HIV-1 vaccine candidate incorporating gp41 subunit antigens intended to induce mucosal antibodies and prevent mucosal transmission; evaluated in preclinical models and a Phase I trial.
Malaria transmission-blocking virosome vaccine candidate
Virosome-based formulations containing malaria antigens developed to reduce or block transmission of Plasmodium falciparum in preclinical models.
Respiratory syncytial virus (RSV) virosomal vaccine with MPLA adjuvant
Virosome-formulated RSV vaccine candidates incorporating a membrane-incorporated monophosphoryl lipid A adjuvant evaluated for immunogenicity and protective capacity in preclinical models.
Allergy immunotherapy using peptide antigens linked to virosomes
Preclinical formulations combining contiguous overlapping peptides (COPs) with virosome carriers aimed at allergen immunotherapy with potential for shortened administration schemes.
Partner cancer immunotherapy vaccine manufacturing
Manufacture and development services for a partner cancer immunotherapy vaccine candidate under an exclusive agreement to support upcoming clinical evaluation.
Services
Preclinical and early clinical supply development and manufacturing services for virosome-formulated vaccine candidates under collaboration or exclusive agreements.
Collaborative R&D projects with academic and research institutes to evaluate recombinant antigens combined with virosome carriers in preclinical models.
Process design and optimization to produce thermostable, solid-form vaccine presentations intended for mucosal routes and reduced cold-chain reliance.
Coordination and participation in funded consortium projects and access to transnational vaccine development infrastructure services to support evaluation and development activities.
Preclinical and early clinical supply development and manufacturing services for virosome-formulated vaccine candidates under collaboration or exclusive agreements.
Collaborative R&D projects with academic and research institutes to evaluate recombinant antigens combined with virosome carriers in preclinical models.
Process design and optimization to produce thermostable, solid-form vaccine presentations intended for mucosal routes and reduced cold-chain reliance.
Coordination and participation in funded consortium projects and access to transnational vaccine development infrastructure services to support evaluation and development activities.
Expertise Areas
- Virosome-based vaccine platform development
- Mucosal immunization and delivery
- Vaccine formulation and thermostability
- Preclinical vaccine development and animal challenge models
Key Technologies
- Virosome (phospholipid vesicle) delivery platform
- Mucosal administration routes (intranasal, sublingual, oral)
- Thermostable solid-form vaccine formulations (powders, tablets, capsules)
- Monophosphoryl lipid A adjuvant incorporation
News & Updates
Mymetics collaborates with PATH Malaria Vaccine Initiative to develop a malaria transmission-blocking vaccine candidate.
The company announced the appointment of Grant E. Pickering as President and CEO and Dr. Christopher S. Henney as Chairman of the Board.
Mymetics signed an exclusive agreement with Imugene to manufacture and develop HER-Vaxx, a cancer immunotherapy planned to enter Phase I/II trials.
A study demonstrating the safety and immunogenicity of Mymetics' HIV-1 vaccine in a Phase I trial involving 24 healthy women.
A detailed report of successful preclinical trials of Mymetics' HIV-1 vaccine published in the journal Immunity.
The US Patent and Trademark Office issued a notice of allowance for the patent application 'Phospholipid Virosome' #10/544,939.
Mymetics collaborates with PATH Malaria Vaccine Initiative to develop a malaria transmission-blocking vaccine candidate.
The company announced the appointment of Grant E. Pickering as President and CEO and Dr. Christopher S. Henney as Chairman of the Board.
Mymetics signed an exclusive agreement with Imugene to manufacture and develop HER-Vaxx, a cancer immunotherapy planned to enter Phase I/II trials.
A study demonstrating the safety and immunogenicity of Mymetics' HIV-1 vaccine in a Phase I trial involving 24 healthy women.
A detailed report of successful preclinical trials of Mymetics' HIV-1 vaccine published in the journal Immunity.
The US Patent and Trademark Office issued a notice of allowance for the patent application 'Phospholipid Virosome' #10/544,939.